您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Granisetron-d3
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Granisetron-d3
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Granisetron-d3图片
CAS NO:1224925-76-1
包装:1mg
市场价:4007元

产品介绍
An internal standard for the quantification of granisetron
Cas No.1224925-76-1
别名格拉司琼-D3
Canonical SMILESCN1[C@H]2C[C@H](NC(C3=NN(C([2H])([2H])[2H])C4=C3C=CC=C4)=O)C[C@@H]1CCC2
分子式C18H21D3N4O
分子量315.4
溶解度Methanol: Soluble
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Granisetron-d3is intended for use as an internal standard for the quantification of granisetron by GC- or LC-MS. Granisetron is an antagonist of the serotonin (5-HT) receptor subtype 5-HT3(Ki= 3.9 nM) with antiemetic activity.1,2It is selective for 5-HT3over 5-HT4receptors (Ki= >1,000 nM).1Granisetron (0.3, 1, and 3 mg/kg, p.o.) increases the latency to a first vomiting episode and reduces the number of vomiting episodes in a canine model of emesis induced by cisplatin .2It also increases the latency to a first vomiting episode and reduces the number of vomiting and retching episodes in a ferret model of emesis induced by doxorubicin and cyclophosphamide when administered at doses of 0.1, 0.3, and 1 mg/kg. Formulations containing granisetron have been used in the prevention of nausea and vomiting associated with chemotherapy.

1.LÓpez-RodrÍguez, M.L., BenhamÚ, B., Morcillo, M.J., et al.Benzimidazole derivatives. 2. Synthesis and structure-activity relationships of new azabicyclic benzimidazole-4-carboxylic acid derivatives with affinity for serotoninergic 5-HT3 receptorsJ. Med. Chem.42(24)5020-5028(1999) 2.Haga, K., Inaba, K., Shoji, H., et al.The effects of orally administered Y-25130, a selective serotonin3-receptor antagonist, on chemotherapeutic agent-induced emesisJpn. J. Pharmacol.63(3)377-383(1993)